User login
Key clinical point: Immune checkpoint inhibitors (ICI) plus radiotherapy (RT) conferred an overall survival (OS) benefit over chemotherapy plus RT after resection of brain metastasis from non-small cell lung cancer (NSCLC).
Major finding: The chemotherapy plus RT group had a shorter median OS than the ICI plus RT group after neurosurgery (11.8 months; 95% CI 9.1-15.2 vs 23.0 months; 95% CI 20.3-53.8; P < .001).
Study details: The data come from a retrospective propensity score-matched cohort study involving 62 NSCLC patients treated with ICI plus RT and 62 treated with chemotherapy plus RT after neurosurgery for brain metastasis, from 2010 to 2021.
Disclosures: No funding information was available. N Frost reported receiving personal fees and nonfinancial support from pharmaceutical companies outside this work. The other authors declared no competing interests.
Source: Wasilewski D et al. Effectiveness of immune checkpoint inhibition vs chemotherapy in combination with radiation therapy among patients with non–small cell lung cancer and brain metastasis undergoing neurosurgical resection. JAMA Netw Open. 2022;5(4):e229553 (Apr 29). Doi: 10.1001/jamanetworkopen.2022.9553
Key clinical point: Immune checkpoint inhibitors (ICI) plus radiotherapy (RT) conferred an overall survival (OS) benefit over chemotherapy plus RT after resection of brain metastasis from non-small cell lung cancer (NSCLC).
Major finding: The chemotherapy plus RT group had a shorter median OS than the ICI plus RT group after neurosurgery (11.8 months; 95% CI 9.1-15.2 vs 23.0 months; 95% CI 20.3-53.8; P < .001).
Study details: The data come from a retrospective propensity score-matched cohort study involving 62 NSCLC patients treated with ICI plus RT and 62 treated with chemotherapy plus RT after neurosurgery for brain metastasis, from 2010 to 2021.
Disclosures: No funding information was available. N Frost reported receiving personal fees and nonfinancial support from pharmaceutical companies outside this work. The other authors declared no competing interests.
Source: Wasilewski D et al. Effectiveness of immune checkpoint inhibition vs chemotherapy in combination with radiation therapy among patients with non–small cell lung cancer and brain metastasis undergoing neurosurgical resection. JAMA Netw Open. 2022;5(4):e229553 (Apr 29). Doi: 10.1001/jamanetworkopen.2022.9553
Key clinical point: Immune checkpoint inhibitors (ICI) plus radiotherapy (RT) conferred an overall survival (OS) benefit over chemotherapy plus RT after resection of brain metastasis from non-small cell lung cancer (NSCLC).
Major finding: The chemotherapy plus RT group had a shorter median OS than the ICI plus RT group after neurosurgery (11.8 months; 95% CI 9.1-15.2 vs 23.0 months; 95% CI 20.3-53.8; P < .001).
Study details: The data come from a retrospective propensity score-matched cohort study involving 62 NSCLC patients treated with ICI plus RT and 62 treated with chemotherapy plus RT after neurosurgery for brain metastasis, from 2010 to 2021.
Disclosures: No funding information was available. N Frost reported receiving personal fees and nonfinancial support from pharmaceutical companies outside this work. The other authors declared no competing interests.
Source: Wasilewski D et al. Effectiveness of immune checkpoint inhibition vs chemotherapy in combination with radiation therapy among patients with non–small cell lung cancer and brain metastasis undergoing neurosurgical resection. JAMA Netw Open. 2022;5(4):e229553 (Apr 29). Doi: 10.1001/jamanetworkopen.2022.9553